bioMérieux (France)
bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
For over 45 years, bioMérieux has contributed its expertise to the fight against infectious diseases, an area in which in vitro diagnostics have become increasingly important.
Physicians rely on the identification of an infectious agent to determine the appropriate treatment for each patient. Monitoring chronic infections requires highly sensitive diagnostic methods that can provide the necessary quantitative information to adjust therapy (for example, viral load monitoring for patients living with HIV).
Diagnostics are also essential to detect and monitor the course of healthcare-associated infections and emerging diseases, thus preventing their spread. bioMérieux is a world leader in microbiology with unique know-how and expertise in microbial culture, detection, identification, antimicrobial resistance testing and related expert interpretation software to analyze resistance trends and recognize uncommon resistance mechanisms. The company also masters the two other core technologies required for developing in vitro diagnostics: immunoassays and molecular biology.
bioMérieux R&D's primary goal is to improve patients' health by delivering results more rapidly through increased laboratory automation. It focuses on infectious diseases that represent major public health challenges: sepsis, healthcare-associated infections, HIV and tuberculosis.
